Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.

Journal for immunotherapy of cancer - 1 May 2021

de Kouchkovsky Ivan, Zhang Li, Philip Errol J, Wright Francis, Kim Daniel M, Natesan Divya, Kwon Daniel, Ho Hansen, Ho Son, Chan Emily, Porten Sima P, Wong Anthony C, Desai Arpita, Huang Franklin W, Chou Jonathan, Oh David Y, Pruthi Raj S, Fong Lawrence, Small Eric J, Friedlander Terence W, Koshkin Vadim S

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitors (ICI) can achieve durable responses in a subset of patients with locally advanced or metastatic urothelial carcinoma (aUC). The use of tumor genomic profiling in clinical practice may help suggest biomarkers to identify patients most likely to benefit from ICI. METHODS: We undertook a retrospective analysis of patients treated with an ICI for aUC at a large academic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Predictive Value of Tests

Share to Progression-Free Survival

Share to Risk Assessment

Share to Telomerase

Share to Urologic Neoplasms

Share to Urothelium

Source

Open in PubMed Open full text

Identifiers

PMID: 33980590
DOI: 10.1136/jitc-2020-002127
PMCID: PMC8118032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.PMID 33980590Read ↗

TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinomaSemantic proximity Read ↗

A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.Semantic proximity Read ↗

TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.Semantic proximity Read ↗

Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma.Semantic proximity Read ↗

The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival ProbabilitySemantic proximity Read ↗

Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.Semantic proximity Read ↗

Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.Semantic proximity Read ↗

TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type.Semantic proximity Read ↗

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.Semantic proximity Read ↗

Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancerSemantic proximity Read ↗

The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohortSemantic proximity Read ↗

Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.